The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
about
Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetineReboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsNeurotransmitter transporters and their impact on the development of psychopharmacologyThe noradrenergic paradox: implications in the management of depression and anxietyA systematic review of reboxetine for treating patients with attention deficit hyperactivity disorderExploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics StudyErotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjectsDifferential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomesEstimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetineAdverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individualsAn overview of seasonal affective disorder and its treatment options.WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.Monoamine reuptake inhibitors in Parkinson's disease.Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy.Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety.Clinically significant drug interactions with newer antidepressants.High-throughput screening for norepinephrine transporter inhibitors using the FLIPRTetra.Metal-free one-pot synthesis of 2-substituted and 2,3-disubstituted morpholines from aziridines.Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects.Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.A general, enantioselective synthesis of protected morpholines and piperazines.Enantioselective synthesis of C2-functionalized, N-protected morpholines and orthogonally N,N'-protected piperazines via organocatalysis(2R,6S)-tert-Butyl 2-(benzhydryl-carbamo-yl)-6-methyl-morpholine-4-carboxyl-ateComparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol.Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?Stereoselective bromofunctionalization of alkenes.No evidence for enhanced extinction memory consolidation through noradrenergic reuptake inhibition-delayed memory test and reinstatement in human fMRI.Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy?Rearrangement of beta-amino alcohols and application to the synthesis of biologically active compounds.Highly enantioselective synthesis of linear beta-amino alcohols.Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.Antidepressants are neuroprotective against nutrient deprivation stress in rat hippocampal neurons.Stereoselective synthesis of (2S,3R)- and (2R,3S)-iodoreboxetine; potential SPECT imaging agents for the noradrenaline transporter.Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials.Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation.
P2860
Q24602850-1996187A-EB99-4EFC-89A9-9D179DE6B3B8Q24632255-7619BE19-9FAC-480D-82E8-19810E187A2DQ24670273-0E3FA105-9EA3-40B0-812E-10A5EF9A5F2EQ26752868-729503DD-FC5D-45F3-86B9-9D91413197B0Q28251940-6F7B4C7D-A063-4890-A664-EB9CD3CB242BQ28833274-68E11A0C-5CFD-4134-8936-8E0498722D13Q30630798-3D94204E-D7F6-44D4-97B7-436CB4C9D32AQ33569581-72E3F363-0464-4B9E-84B8-D644C2643EF8Q33870452-C1FF1446-D205-4B51-BAE1-41A5F80F6E47Q33906501-076C8C48-3BE8-4F58-8AC2-05CB631FBDA3Q34090987-B7966331-0680-43F6-968D-C8D61B0C92D5Q34112969-45F32380-FB90-4630-82EC-9E2C4B40DB86Q34496400-51C8377E-3253-49F8-83C9-98B9969A53ACQ35165280-22312711-F560-4697-9062-6F40B52F885AQ36287901-BAC00387-3A68-4098-BAE2-9F70CA3D6582Q36635608-1112A3F9-605E-4CB4-BDDA-DF4234554BE1Q36637666-B3B6DBF7-D6D7-4C19-8AD0-CE407A6AED80Q36664940-DB254F21-A1D1-4165-9C2B-27941E5ADC65Q37329171-C169C05C-CFB8-430F-A9A4-5B0731B24F34Q37968621-F350F54A-AACB-44A7-BC70-48D88E46B3FAQ40145100-3D0BE065-B3EB-4A68-B5E6-30557CEA7288Q40260906-C9A5EBA6-64CA-4E29-8C4F-072752FAC19BQ40829831-8E5AA510-7758-4118-9527-40DCF864A05DQ41725208-EE1C29FC-058F-4714-854B-4D1993CA1617Q42015236-12E7474E-7786-4C05-B592-4199C0449371Q42019869-664A2299-8F0D-4E95-8627-E50E459EEC79Q42113340-D2ED99CA-5D07-4711-907F-8EBC0AD5694FQ42123694-145E3191-A184-4BC3-98C6-12C68F0D699AQ42361149-BBC4653D-F60D-4271-88A4-13E3236C0510Q42630317-63CF0B1F-E8E4-4CE9-AE7D-E62EA00CE107Q43832947-A9657E61-EE20-4D37-BF59-8B77BEE84E0FQ44773470-D1BC0379-F708-4661-A2CE-5BB3A1720DA9Q44889816-31B0D0CF-2EEE-43FC-8C5D-40B43B16F840Q46029166-93FFA1FB-9D4A-4216-8CEA-6B2720436DC6Q46196376-F606D344-DDB1-486F-9930-1F0FD0A1E7F3Q46202396-43982419-24D4-4D94-817B-46CC1FB6D262Q46511170-092E5414-9CB7-4C1D-B126-B48F73D66B51Q46532813-B61CDA0B-986D-42B9-96B5-9B30D30D8B6EQ47158437-336E0508-4E83-439D-B1C1-F2CF357C2BFCQ47644422-9DBB5453-CD70-4ED1-9CEB-B35A03C3DB59
P2860
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The selective norepinephrine r ...... ological and clinical profile.
@ast
The selective norepinephrine r ...... ological and clinical profile.
@en
type
label
The selective norepinephrine r ...... ological and clinical profile.
@ast
The selective norepinephrine r ...... ological and clinical profile.
@en
prefLabel
The selective norepinephrine r ...... ological and clinical profile.
@ast
The selective norepinephrine r ...... ological and clinical profile.
@en
P2093
P2860
P1476
The selective norepinephrine r ...... cological and clinical profile
@en
P2093
Erik H F Wong
Jacqueline K Filipiak-Reisner
Joseph C Fleishaker
Mark T Brown
Mihály Hajós
P2860
P356
10.1111/J.1527-3458.2004.TB00002.X
P577
2004-01-01T00:00:00Z